Century Therapeutics Inc
NASDAQ:IPSC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kidoz Inc
XTSX:KDOZ
|
CA |
|
W
|
Wilh Wilhelmsen Holding ASA
XBER:WML1
|
NO |
Century Therapeutics Inc
Total Current Assets
Century Therapeutics Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Century Therapeutics Inc
NASDAQ:IPSC
|
Total Current Assets
$120.8m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Total Current Assets
$1.6B
|
CAGR 3-Years
17%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
17%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
Century Therapeutics Inc
Glance View
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 170 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The firm's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.
See Also
What is Century Therapeutics Inc's Total Current Assets?
Total Current Assets
120.8m
USD
Based on the financial report for Dec 31, 2025, Century Therapeutics Inc's Total Current Assets amounts to 120.8m USD.
What is Century Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
-28%
Over the last year, the Total Current Assets growth was -38%. The average annual Total Current Assets growth rates for Century Therapeutics Inc have been -28% over the past three years .
